That's fine but Amarin is going to have to be much more attractive to garner any interest. It is too soon, as we need to get a number of things in order. More reimbursement decisions in ROW (positive ones) and more of an idea of what is happening with the U.S. market, and any new possible formulations to bring to market.
Forget "The He said she said" talk, don't mean a thing. They better have something good to announce on that conference or the stock will take another dive. Short of that, they should just cancel that conference.
Market Data 
Markets 
AI
